65,437 trials
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
Fibromyalgia
Primary: Change From Baseline in Mean Systolic Blood Pressure Following 12-hour Period Post-AM Dose at Visit 4 — -0.9; 4.0; 0.2; 3.7 mm Hg
Overactive Bladder
Primary: Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment). — -1.46; -1.61; -1.72 number of episodes…
Migraine Disorders
Primary: Safety and Tolerability of Single Doses of Rizatriptan in Pediatric Migraineurs — 0; 0; 0; 3 Participants
Gaucher Disease, Type 1 · Cerebroside Lipidosis Syndrome · Glucocerebrosidase Deficiency Disease
Primary: Number of Participants With Clinical Success at Month 24/Discontinuation — 21; 36; 0.808; 0.632 patients
Chronic Bronchitis
Primary: Percentage of Clinical Cure (Success) at Test of Cure Visit(Clinical Per Protocol Population) — 93.0; 94.2; 7.0; 5.8 percent
Stroke
Primary: Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only) — 916; 898 Participants — p=0.7830
Relapsing Multiple Sclerosis
Primary: Percent Change in Global Side Effects (GSE) on Multiple Sclerosis Treatment Concerns Quesionnaire (MSTCQ) — 5.0 percent change — p=<0.001
Crohn's Disease
Primary: Number of Participants in Clinical Remission at Treatment Week 20. Clinical Remission Defined as Harvey Bradshaw Index (HBI) Score Less Than 5. — 492 Participants
Acne Vulgaris
Primary: Assessment of Facial Irritation and Cutaneous Effects — 4.8; 3.9; 8.8; 6.7 Ordinal data treated as interval
Asthma
Primary: Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 35 — -0.050; -0.040; -0.023 Giga Units per Liter (GI/L)
Infection, Human Immunodeficiency Virus I · HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks — 81; 82; 19; 18 Percentage of participants
Hypothermia
Primary: Neonatal Intensive Care Unit (NICU) Admission Temperature — 36.5; 36.1 Celsius degrees — p=0.445
Type 1 Diabetes
Primary: Change in Glycated Hemoglobin (HbA1c) From Baseline to 26 Weeks in the Continuous Glucose Monitoring (CGM) and Control Groups (for the Cohort With Baseline HbA1c >=7.0%…
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline in Total Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Score at 7 Weeks — -28.6 Units on a scale — p=< 0.0001